Ligand Pharmaceuticals: Pay

Ligand Pharmaceuticals paid its 3 named executives $19.6M in total in FY2025 (Dec). CEO Todd C. Davis was paid $11.5M of that.

Pay$100 in the stock at the end of FY21 → $122
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Todd C. DavisChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Tavo EspinozaChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Andrew ReardonChief Legal Officer and Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 4 peers with pay on file was $5.5M. CEO pay of Ligand Pharmaceuticals for that year is not on file.

  1. 1Collegium Pharmaceutical
  2. 2Travere Therapeutics
  3. 3Agios Pharmaceuticals
  4. 4Innoviva
  5. 5Ligand PharmaceuticalsNot disclosed
  6. 6Axsome TherapeuticsNot disclosed
  7. 7Catalyst PharmaceuticalsNot disclosed
  8. 8Coherus BioSciencesNot disclosed
  9. 9Corcept TherapeuticsNot disclosed
  10. 10Deciphera PharmaceuticalsNot disclosed
  11. 11Heron TherapeuticsNot disclosed
  12. 12Intercept PharmaceuticalsNot disclosed
  13. 13Ironwood PharmaceuticalsNot disclosed
  14. 14REGENXBIONot disclosed
  15. 15Rhythm PharmaceuticalsNot disclosed
  16. 16Theravance BiopharmaNot disclosed
  17. 17Vanda PharmaceuticalsNot disclosed
  18. 18VericelNot disclosed
  19. 19XencorNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.